D Wave Quantum Inc vs Revvity Inc — how do they compare? D Wave Quantum Inc trades at $14.57 (market cap $5.54B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 3.1× D Wave Quantum Inc's market cap, and Revvity Inc pays a 0.18% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D Wave Quantum Inc for 32 Days and Revvity Inc for 12 Days on average.
| QBTS | RVTY | |
|---|---|---|
Market Cap | $5.54B | $16.98B |
Volume | 16,671,452 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $44.78 | $157.36 |
52-Week Low | $12.98 | $82.26 |
Typical Hold Time | 32 Days | 12 Days |
Enterprise Value | $5.04B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
D-Wave Quantum (QBTS) trades at $14.60, down 4.07% with a bearish technical signal despite unanimous analyst buy ratings and a $34.38 consensus target. The quantum computing company shows concerning fundamentals with a P/S ratio of 421.36 and negative profitability metrics, including a -2,001.59% net income margin. Recent quarterly earnings have been mixed, missing expectations in Q4 2025 and Q2 2026 while beating in Q1 2026.
While analyst optimism remains high with 100% buy ratings, significant financial risks persist including ongoing losses, negative cash flow projections for 2026, and multiple fraud investigations. The stock faces substantial execution risk in the competitive quantum computing space, though long-term potential exists if the company can achieve commercial scalability and positive cash flow generation.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →